Paper39375281
Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History.
Blauvelt A and 5 others. Dermatol Ther (Heidelb), 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History. Papers, record 39375281. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39375281
- Disease
- atopic eczema238 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03745638 | Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03745651 | TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | Derived from the trial | Yes | ClinicalTrials.gov |
References8
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33957195 | Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. | J Am Acad Dermatol | 2021 | https://conductscience.org/library/papers/33957195 | PubMed |
| 2 | 37943240 | Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. | J Am Acad Dermatol | 2024 | https://conductscience.org/library/papers/37943240 | PubMed |
| 3 | 36641009 | Guidelines of care for the management of atopic dermatitis in adults with topical therapies. | J Am Acad Dermatol | 2023 | https://conductscience.org/library/papers/36641009 | PubMed |
| 4 | 28803668 | When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. | J Am Acad Dermatol | 2017 | https://conductscience.org/library/papers/28803668 | PubMed |
| 5 | 32738956 | Atopic dermatitis. | Lancet | 2020 | https://conductscience.org/library/papers/32738956 | PubMed |
| 6 | 24813302 | Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. | J Am Acad Dermatol | 2014 | https://conductscience.org/library/papers/24813302 | PubMed |
| 7 | 20130243 | Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. | Blood | 2010 | https://conductscience.org/library/papers/20130243 | PubMed |
| 8 | 36574595 | Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. | J Am Acad Dermatol | 2023 | https://conductscience.org/library/papers/36574595 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42004157 | Real-World Treatment Patterns in Patients with Atopic Dermatitis Initiating Ruxolitinib Cream: A 12-Month Follow-Up Analysis of a US Payer Claims Database. | Clinicoecon Outcomes Res | 2026 | https://conductscience.org/library/papers/42004157 |
Source PubMed
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| RUXOLITINIB | CHEMBL1789941 | Derived from the trial | 2 | https://conductscience.org/library/drugs/CHEMBL1789941 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39375281
GET https://conductscience.org/api/papers/v1/39375281/authors